CCTG HN11 SELECT has now opened to accrual across Canada and sites in the US. The trial is a randomized, controlled, phase III clinical trial for patients with lateralized oropharyngeal carcinoma (OPC)
MAIN-CAV: Maintenance Cabozantinib and Avelumab vs Maintenance Avelumab After First-Line Platinum Based Chemotherapy in Metastatic Urothelial Cancer
Tailored Adjuvant Therapy in POLE-mutated and p53-wildtype/NSMP Early Stage Endometrial Cancer (RAINBO BLUE & TAPER)
SPECT-CT Guided ELEctive Contralateral Neck Treatment in Lateralized Oropharyngeal Cancer (SELECT)
The recently launched Centre for Health Innovation, aims to connect researchers from across multiple disciplines to tackle the most pressing human health challenges. A critical part of the centre will be a new home for the CCTG Tumour Tissue Data Repository and includes a large-scale expansion of its histopathology and biobanking resources.
MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML
Master Screening and Reassessment Protocol (MYELOMATCH) for the NCI myeloMATCH clinical trials
Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)
Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
RAINBO: Refining Adjuvant treatment IN endometrial cancer Based On molecular features. The MMRD-GREEN trial
Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma
PET Response Adapted Design Comparing ABVD +/- ISRT with A2VD +/- ISRT in Patients with Stage IA/IIA Hodgkin Lymphoma (RADAR)
PembROlizumab with or without Microbial EcOsystem ThErapeutic 4 (MET4) in Advanced Head and Neck Squamous Cell Carcinoma (PROMOTE-HN)
Comparing Stereotactic Body Radiation Therapy (SBRT) to Standard Palliative Radiation Treatment (ON-TASC Study)
A Phase II Pre-operative Trial of JDQ433 in Surgically Resectable NSCLC
De-escalation of Chemo in HER-2+, ER-, Node-negative, breast cancer patients who achieved complete response after chemo and Dual HER-2 blOckade (DECRESCENDO)
Adjuvant Treatment Guided by Response Post Neoadjuvant Therapy for Stage III Melanoma
NET RETREAT: 177Lutetium- DOTATATE Retreatment vs. Everolimus in Metastatic/unresectable Midgut NET
Evaluating the Impact of SBRT with or without Nirapariib in Metastatic Hormone Sensitive Prostate Cancer Treated with ADT and Androgen Axis Directed Therapy
Androgen Suppression combined with Elective Nodal and a Dose Escalated Boost. Stereotactic Body Radiation Therapy vs Brachytherapy Boost (ASCENDE-SBRT)
Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients with Alterations in DNA Damage Response Genes
The SEEMLESS Study: A randomized trial of a SmartphonE App-based MindfuLnEss intervention for cancer SurvivorS
STRatIfication of Vulvar squamous cell carcinoma by HPV and p53 status to guide Excision: STRIVE Study
Oral presentation by Dr Laura Dawson at the ASCO Gastrointestinal Cancer Symposium 2023 of results for the Canadian Cancer Trials Group (CCTG) HE1 phase III study of palliative radiation therapy for symptomatic hepatocellular carcinoma and liver metastases.
This Canadian study investigated whether one dose of palliative radiation therapy directed to the liver in combination with the standard, best supportive care could help to reduce pain and discomfort for patients with end-stage primary or metastatic liver cancer. This patient population are often not a good fit for standard therapies, and experience pain that cannot be controlled well with pain medication alone. The goal of a palliative radiation intervention is to improve pain management and quality of life.
“This study found that one treatment of simple radiation therapy delivered to the liver resulted in clinically important and statistically significant reduction in patient reported pain one month following treatment,” says Dr Laura Dawson, the HE1 study chair and a Radiation Oncologist at Princess Margaret Hospital, UHN. “The majority of patients treated experienced reduced pain that allowed them to enjoy more quality time near the end of their life.”
The Canadian Cancer Trials Group with study lead Dr Elena Elimova at Princess Margaret Cancer Centre were granted $3,744,953 over 3 years by CIHR to fund the CCTG GA4 study in HER2 overexpressing advanced gastroesophageal adenocarcinoma.
EN10 (RAINBO BLUE & TAPER) is a new Canadian clinical trial that is applying state-of-the-art molecular testing to classify post-surgery treatments in early-stage endometrial cancer to identify people at low risk of cancer recurrence based on the molecular features of their tumours.
Three CCTG trials were recently awarded nearly $7.5M from the Canadian Institutes of Health Research (CIHR) 2022 Spring Project Grant competition.
It was recently announced that ExCELLirate Canada has successfully been granted a Research Infrastructure award of $4,159,049 by the Ontario Research Fund for the Innovation Fund Project Grant "ExCELLirate Canada: Expanding CELL-based Immunotherapy Research Acceleration for Translation and Evaluation".
Cancer is not a single disease; it is hundreds. Cancers of the lung, breast, prostate, and colon are the most common forms of the disease, and account for about half of all diagnoses. But less common forms of cancer also account for about half of diagnoses, and these are not as well studied.
CCTG has launched a patient-centred observational study: SC27 Living With Cancer in the Time of COVID-19: A Cohort Study of the Impact of the COVID-19 Pandemic on Cancer Patients During Treatment and Survivors. The aim of this study is to examine the emotional and physical consequences of living with cancer during this pandemic and the impact it may have on your quality of life and changes in your cancer care and follow-up.
The establishment of the Britton Smith Foundation Clinical Trials Fund. A thank you from Doug Kane, senior manager, Canadian Cancer Society FLA & The Waterways Community Office.
Once the initial shock of a cancer diagnosis wears off, patients and families are left with questions. Lots and lots of questions. It might come as a relief to know that some of the most brilliant, accomplished scientists from around the world are listening.
“The biggest question we ask is the one that all cancer patients have,” says CCTG Scientific Director Dr. Janet Dancey. “What is the best treatment?”
Translational Lung Cancer Research 10: 826 - 838, 21 FFung AS;Karimi M;Michiels S;Seymour L;Brambilla E;Le-Chevalier T;Soria JC;Kratzke R;Graziano SL;Devarakonda S;Govindan R;Tsao MS;Shepherd FA;Collaborative Group obotL;
J Clin Oncol , 2023Speers CW;Symmans WF;Barlow WE;Trevarton A;The S;Du L;Rae JM;Shak S;Baehner R;Sharma P;Pusztai L;Hortobagyi GN;Hayes DF;Albain KS;Godwin A;Thompson A;
J Clin Oncol 41: 233 - 242, 2023Kennecke HF;O'Callaghan CJ;Loree JM;Moloo H;Auer R;Jonker DJ;Raval M;Musselman R;Ma G;Caycedo-Marulanda A;Simianu VV;Patel S;Pitre LD;Helewa R;Gordon VL;Neumann K;Nimeiri H;Sherry M;Tu D;Brown CJ;
J Clin Oncol 41: 243 - 254, 2023Brown JC;Ma C;Shi Q;Fuchs CS;Meyer J;Niedzwiecki D;Zemla T;Couture F;Kuebler P;Kumar P;Lewis D;Tan B;Krishnamurthi S;O'Reilly EM;Shields AF;Meyerhardt JA;
J Clin Oncol 40: 248 - 248, 2022Gupta A;O'Callaghan CJ;Zhu L;Jonker DJ;Wong R;Colwell B;Moore MJ;Karapetis CS;Tebbutt NC;Shapiro JD;Tu D;Booth CM;
Int J Gynecol Cancer 33: 109, 2022RAINBO Research Consortium;
J Clin Oncol , 2022Pagani O;Walley BA;Fleming GF;Colleoni M;Lang I;Gomez HL;Tondini C;Burstein HJ;Goetz MP;Ciruelos EM;Stearns V;Bonnefoi HR;Martino S;Geyer CE;Chini C;Puglisi F;Spazzapan S;Ruhstaller T;Winer EP;Ruepp B;Loi S;Coates AS;Gelber RD;Goldhirsch A;Regan MM;Francis PA;
Current Oncology 29: 8591 - 8599, 2022Rushton M;Pudwell J;Wei X;Powell M;Richardson H;Velez MP;